Last reviewed 2026-04-22 · How we verify

Paroxetine + Venlafaxine XR

Paroxetine + Venlafaxine XR is a SSRI/SNRI combination Small molecule drug developed by Ministry of Health & Welfare, Korea. It is currently FDA-approved for Major depressive disorder, Generalized anxiety disorder. Also known as: seroxat, efexor XR.

This combination of paroxetine (SSRI) and venlafaxine XR (SNRI) increases serotonin and norepinephrine availability in the brain by inhibiting their reuptake at the synaptic level.

This combination of paroxetine (SSRI) and venlafaxine XR (SNRI) increases serotonin and norepinephrine availability in the brain by inhibiting their reuptake at the synaptic level. Used for Major depressive disorder, Generalized anxiety disorder.

At a glance

Mechanism of action

Paroxetine selectively inhibits serotonin reuptake, while venlafaxine XR inhibits both serotonin and norepinephrine reuptake. Together, they provide dual monoamine enhancement to treat depression and anxiety disorders. This combination approach may offer broader neurochemical coverage than either agent alone, though it carries increased risk of serotonin syndrome and drug interactions.

Approved indications

• Major depressive disorder
• Generalized anxiety disorder

Common side effects

• Nausea
• Headache
• Dizziness
• Sexual dysfunction
• Insomnia
• Serotonin syndrome (rare)

Key clinical trials

• A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (PHASE4)
• A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (PHASE2)
• Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
• A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (PHASE3)
• Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (PHASE4)
• Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
• Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD (PHASE4)
• A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Paroxetine + Venlafaxine XR CI brief — competitive landscape report
• Paroxetine + Venlafaxine XR updates RSS · CI watch RSS
• Ministry of Health & Welfare, Korea portfolio CI

Frequently asked questions about Paroxetine + Venlafaxine XR

Related

• Drug class: All SSRI/SNRI combination drugs
• Target: All drugs targeting Serotonin transporter (SERT), Norepinephrine transporter (NET)
• Manufacturer: Ministry of Health & Welfare, Korea — full pipeline
• Therapeutic area: All drugs in Psychiatry/Mental Health
• Indication: Drugs for Major depressive disorder
• Indication: Drugs for Generalized anxiety disorder
• Also known as: seroxat, efexor XR
• Compare: Paroxetine + Venlafaxine XR vs similar drugs
• Pricing: Paroxetine + Venlafaxine XR cost, discount & access